首頁 > 市場調查報告書 > 製藥

神經疾病

市場調查報告書

商品編碼

2051426

脊髓性肌肉萎縮症市場：按類型、療法、年齡層、給藥途徑、分銷管道和地區分類

Spinal Muscular Atrophy Market, by Type, by Treatment, by Age Group, by Route of Administration, by Distribution Channel, By Geography

出版日期: 2026年04月01日 | 出版商:

Coherent Market Insights | 英文 156 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

脊髓性肌肉萎縮症 (SMA) 市場預計在 2026 年達到 22.955 億美元，預計到 2033 年將達到 56.389 億美元。預計從 2026 年到 2033 年，該市場將以 13.7% 的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	22.955億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	13.70%	2033年市場規模預測：	56.389億美元

脊髓性肌肉萎縮症（SMA）是一種遺傳性疾病，會影響周邊神經系統、中樞神經系統以及隨意肌肉（骨骼肌）的運動。之所以稱之為“肌肉”，是因為它主要影響肌肉。無法接收到神經細胞刺激的肌肉會發生萎縮。「萎縮」是一個醫學術語，指的是無法接收到神經細胞刺激的肌肉體積縮小。 SMA是運動神經元疾病，會導致脊髓中稱為運動神經元的神經細胞流失。它主要發生於嬰兒童，但也可能發生於成人。 SMA患者遺傳了兩個SMN1（運動神經元存活基因）基因拷貝，這兩個基因要麼缺失，要麼發生突變。

市場動態

預計市場主要參與者不斷推出新產品將推動預測期內市場成長。例如，2022年8月，日本製藥公司中外製藥株式會社宣布推出“Evrisdi 60mg乾糖漿（通用名：lisdipram）”，用於治療脊髓性肌肉萎縮症（SMA）。

此外，預計大型企業將擴大採用非內生性策略，例如合作和聯合研究，將在預測期內推動市場成長。例如，2022年3月，脊髓性肌肉萎縮症基金會（全球領先的脊髓性肌肉萎縮症研究資助機構）與美國製藥公司PTC Therapeutics, Inc.達成一項新的合作協議，旨在開發新的治療方法和再生藥物，以進一步推進脊髓性肌肉萎縮症和其他神經肌肉疾病的科學研究。

本次調查的主要特點

本研究確定了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究基於以下參數分析了全球脊髓性肌肉萎縮症 (SMA) 市場的主要參與者：公司亮點、產品系列、關鍵亮點、財務績效和策略。
透過利用本報告中的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
全球脊髓性肌肉萎縮症市場報告的目標受群眾外包括該行業的各類相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。 ¹
透過分析全球脊髓性肌肉萎縮症市場時所使用的各種策略矩陣，相關人員將能夠更輕鬆地做出決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第10章競爭格局

Biogen
CYTOKINETICS
F. Hoffmann-La Roche Ltd
Genentech, Inc.
PTC Therapeutics, Inc.
Novartis AG
Ionis Pharmaceuticals
Chugai Pharmaceutical Co., Ltd.
NMD PHARMA A/S
Astellas Pharma Inc.

第11章分析師建議

機會分析
分析師意見
Coherent Opportunity Map

第12章

參考
調查方法

簡介目錄

Product Code: CMI1920

Spinal Muscular Atrophy Market is estimated to be valued at USD 2,295.5 Mn in 2026 and is expected to reach USD 5,638.9 Mn by 2033, growing at a compound annual growth rate (CAGR) of 13.7% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 2,295.5 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	13.70%	2033 Value Projection:	USD 5,638.9 Mn

Spinal muscular atrophy (SMA) is a genetic disease that affects the peripheral nervous system, central nervous system, and voluntary muscle movement (skeletal muscle). SMA is muscular since it primarily affects muscles, which do not receive impulses from the nerve cells. Atrophy is the medical term for shrinking, which is what muscles do when they are not stimulated by nerve cells. SMA is a motor neuron disease that includes the loss of nerve cells termed motor neurons in the spinal cord. It mostly affects infants and children but can also develop in adults. An individual with SMA inherits two copies of a faulty (mutated) or missing survival motor neuron 1 (SMN1) gene.

Market Dynamics

The increasing product launches by the key players in the market are expected to drive the market growth over the forecast period. For instance, in August 2022, Chugai Pharmaceutical Co., Ltd., a drug manufacturer operating in Japan, announced that it had launched Evrysdi Dry Syrup 60 mg (generic name: risdiplam) for the treatment of spinal muscular atrophy (SMA).

Moreover, the increasing adoption of inorganic strategies such as partnerships and collaborations by the key players is expected to drive the market growth over the forecast period. For instance, in March 2022, the Spinal Muscular Atrophy Foundation, the leading funder of SMA research worldwide, and PTC Therapeutics, Inc., a U.S. based pharmaceutical company, entered into a new collaboration focused on developing new treatments and regenerative medicine to further advance scientific research in SMA and other neuromuscular disorders.

Key features of the study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global spinal muscular atrophy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Biogen, CYTOKINETICS, Hoffmann-La Roche Ltd, Genentech, Inc., PTC Therapeutics, Inc., Novartis AG, Ionis Pharmaceuticals, Chugai Pharmaceutical Co., Ltd., NMD PHARMA A/S, and Astellas Pharma Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global spinal muscular atrophy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts1
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global spinal muscular atrophy market

Market Segmentation

Global Spinal Muscular Atrophy Market, By Type (Revenue, USD Mn, 2021 - 2033)
Type I
Type II
Type III
Type IV
Global Spinal Muscular Atrophy Market, By Treatment (Revenue, USD Mn, 2021 - 2033)
Gene Therapy
Disease-modifying drugs
Global Spinal Muscular Atrophy Market, By Age Group (Revenue, USD Mn, 2021 - 2033)
Infant
Adult
Global Spinal Muscular Atrophy Market, By Route of Administration (Revenue, USD Mn, 2021 - 2033)
Oral
Injectables
Global Spinal Muscular Atrophy Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Spinal Muscular Atrophy Market, By Region (Revenue, USD Mn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Company Profiles
Biogen, CYTOKINETICS
F. Hoffmann-La Roche Ltd
Genentech, Inc.
PTC Therapeutics, Inc.
Novartis AG
Ionis Pharmaceuticals
Chugai Pharmaceutical Co., Ltd.
NMD PHARMA A/S
Astellas Pharma Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Treatment
- Market Snapshot, By Age Group
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Acquisitions and Partnerships Scenario
Technological Advancements
Regulatory Scenario
PEST Analysis
Product Launches

4. Global Spinal Muscular Atrophy Market, By Type, 2021 - 2033, (US$ Million)

Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Type I
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Type II
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Type III
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Type IV
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)

5. Global Spinal Muscular Atrophy Market, By Treatment, 2021 - 2033, (US$ Million)

Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Gene Therapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Disease-modifying drugs
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)

6. Global Spinal Muscular Atrophy Market, By Age Group, 2021 - 2033, (US$ Million)

Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Infant
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Adult
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)

7. Global Spinal Muscular Atrophy Market, By Route of Administration, 2021 - 2033, (US$ Million)

Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Injectables
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)

8. Global Spinal Muscular Atrophy Market, By Distribution Channel, 2021 - 2033, (US$ Million)

Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)

9. Global Spinal Muscular Atrophy Market, By Region, 2021 - 2033, (US$ Million)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2021 - 2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Age, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Age, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Age, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
  - UK
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Age, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Age, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Age, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (US$ Million)
  - North Africa
  - Central Africa
  - South Africa

10. Competitive Landscape

Biogen
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
CYTOKINETICS
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
F. Hoffmann-La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Genentech, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
PTC Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Ionis Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Chugai Pharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
NMD PHARMA A/S
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Astellas Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies